Synonyms: CVM-1118 | TRX 818 | TRX-818
Compound class:
Synthetic organic
Comment: Foslinanib (CVM-1118) is an orally bioavailable protein kinase inhibitor with antiangiogenic and antineoplastic activities [1].
|
|
No information available. |
Summary of Clinical Use |
Foslinanib (CVM-1118) has advanced to phase 2 clinical evaluation in oncology indications. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03582618 | CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma | Phase 2 Interventional | TaiRx, Inc. | ||
NCT03600233 | Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors | Phase 2 Interventional | TaiRx, Inc. | ||
NCT04336124 | Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients | Phase 1 Interventional | TaiRx, Inc. |